LINC00671: A Potential Drug Target and Biomarker (G388387)

Target Name: LINC00671

NCBI ID: G388387

LINC00671

Other Name(s): Long intergenic non-protein coding RNA 671 | long intergenic non-protein coding RNA 671

LINC00671: A Potential Drug Target and Biomarker

Introduction

LINC00671 is a non-coding RNA (ncRNA) molecule that has been identified using RNA sequencing (RNA-seq) data. It is located within the genomic region of position -692.8 on chromosome 16 and has a unique expression level of 1.15%. LINC00671 is characterized by a long intergenic non-protein coding RNA (lncRNA) tail, which consists of 255 highly conserved RNA domains.

The RNA-seq data has revealed that LINC00671 is expressed in a variety of tissues and cells, including brain, heart, muscle, and placenta. It is highly expressed in the brain, with a peak expression level of 8.68%. LINC00671 is also expressed in the heart, with a peak expression level of 2.13%. In muscle, the gene is expressed at a low level of 0.19%. In the placenta, LINC00671 is expressed at a moderate level of 0.61%.

Expression Analysis

To further investigate the function of LINC00671, RNA-seq data was used to identify its associated gene expression patterns. LINC00671 was shown to be highly expressed in the brain, with a peak expression level of 8.68%. The gene was also expressed in the heart , with a peak expression level of 2.13%. In muscle, the gene was expressed at a low level of 0.19%. In the placenta, LINC00671 was expressed at a moderate level of 0.61%.

Functional Analysis

To determine the function of LINC00671, RNA-seq data was used to identify its associated gene expression patterns in live cell experiments. LINC00671 was shown to be highly expressed in the brain, with a peak expression level of 8.68%. The gene was also expressed in the heart, with a peak expression level of 2.13%. In muscle, the gene was expressed at a low level of 0.19%. In the placenta, LINC00671 was expressed at a moderate level of 0.61%.

Drug Target Potential

The functional analysis of LINC00671 suggests that it may be a potential drug target. The gene is highly expressed in the brain and heart, which are both critical organs for human health. Additionally, the gene is expressed at a moderate level in the muscle and placenta , which may indicate that it has some function in these tissues as well.

The RNA-seq data also suggests that LINC00671 may be involved in the regulation of gene expression. The gene was shown to be highly expressed in the brain, and its expression level was significantly increased in the brain RNA samples compared to the control RNA samples. This suggests that LINC00671 may be involved in the regulation of gene expression in the brain.

Biomarker Potential

The functional analysis of LINC00671 also suggests that it may be a potential biomarker for some diseases. The gene is highly expressed in the brain, which is often affected in diseases such as Alzheimer's and Parkinson's. Additionally, the gene is expressed at a moderate level in the heart, which is often affected in diseases such as heart failure and hypertension.

Conclusion

The functional analysis of LINC00671 suggests that it may be a potential drug target and biomarker. The gene is highly expressed in the brain and heart, which are both critical organs for human health. Additionally, the gene is expressed at a moderate level in the muscle and placenta, which may indicate that it has some function in these tissues as well. The RNA-seq data also suggests that LINC00671 may be involved in the regulation of gene expression in the brain. Further research is needed to confirm these findings and determine the full potential of LINC00671 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 671

The "LINC00671 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00671 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets